Nguyen Dang, MD
Radiation Oncology · Thibodaux, LANPI 1447493986
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $439 of the $694 with a category attached, or 63.2%. 14 manufacturers reported payments, led by Brainlab, Inc. at 57.4% of the total. Reporting peaked in 2019 at $377 and has fallen 67.3% since, to $123 in 2025.
Across 19 payments — averaging $36.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainlab, Inc.$398
- Exelixis Inc.$39
- Lilly USA, LLC$35
- Puma Biotechnology, Inc.$33
- Cumberland Pharmaceuticals, Inc.$24
- Takeda Pharmaceuticals U.S.A., Inc.$23
- plus $141 from 8 others
What the payments were for
- Travel & lodging$25537%
- Food & beverage$43963%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainlab, Inc. | 3 | $398 |
| Exelixis Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $35 |
| Puma Biotechnology, Inc. | 2 | $33 |
| Cumberland Pharmaceuticals, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| EMD Serono, Inc. | 1 | $17 |
| Pfizer | 1 | $16 |
| Stemline Therapeutics Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
How this compares
$694 in reported general payments places this provider in the 55th percentile of 58 radiation oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pilocarpine Hcl | 11 | $613 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $486 |
| Tamsulosin Hcl | 37 | $287 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Thibodaux
- Chiachien WangShreveport$31K
- James RussoLafayette$20K
- Lane RosenShreveport$10K
- Konstantin KovtunBaton Rouge$3K
- James MazeLake Charles$3K
- Christophe MarquesNew Orleans$3K
- Lawrence MenacheAlexandria$3K
- Troy RichardsShreveport$3K
- Bryce BeardAlexandria$3K
- Andrew ElsonBaton Rouge$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.